Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:CCCC NASDAQ:OCGN NASDAQ:REPL NASDAQ:TBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.61-6.4%$1.39$0.87▼$6.78$160.99M0.74839,202 shs254,301 shsCCCCC4 Therapeutics$2.23+12.1%$1.52$1.09▼$7.66$158.35M2.941.33 million shs4.06 million shsOCGNOcugen$1.14-0.9%$0.94$0.52▼$1.98$332.92M4.184.59 million shs4.18 million shsREPLReplimune Group$10.97+1.9%$9.11$6.44▼$17.00$845.64M0.61895,153 shs2.30 million shsTBIOTelesis Bio$0.30$0.12$0.01▼$6.17$541K0.966,759 shsN/A2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector0.00%+9.15%-0.62%+69.47%-67.93%CCCCC4 Therapeutics0.00%+49.66%+37.65%+79.84%-55.40%OCGNOcugen0.00%+18.01%-5.00%+65.12%-37.02%REPLReplimune Group0.00%+16.08%+10.92%+49.25%+26.97%TBIOTelesis Bio0.00%0.00%+500.00%-70.00%-93.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALECAlector3.9886 of 5 stars3.12.00.04.53.22.50.0CCCCC4 Therapeutics3.0381 of 5 stars3.34.00.00.03.31.70.6OCGNOcugen1.3986 of 5 stars3.51.00.00.02.70.00.0REPLReplimune Group4.0717 of 5 stars3.61.00.04.52.02.50.6TBIOTelesis BioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.14Hold$4.00148.45% UpsideCCCCC4 Therapeutics 2.50Moderate Buy$12.00438.12% UpsideOCGNOcugen 3.00Buy$6.00426.32% UpsideREPLReplimune Group 3.13Buy$20.8389.91% UpsideTBIOTelesis Bio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ALEC, REPL, CCCC, OCGN, and TBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025REPLReplimune GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.006/24/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.006/24/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.006/20/2025REPLReplimune GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight6/2/2025REPLReplimune GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $22.005/12/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.005/12/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.005/9/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.00(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$100.56M1.60N/AN/A$1.29 per share1.25CCCCC4 Therapeutics$35.58M4.45N/AN/A$3.06 per share0.73OCGNOcugen$4.05M82.20N/AN/A$0.10 per share11.40REPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/ATBIOTelesis Bio$225.09M0.00N/AN/A$0.14 per share2.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$119.05M-$1.26N/AN/AN/A-139.74%-100.58%-25.15%8/6/2025 (Estimated)CCCCC4 Therapeutics-$105.32M-$1.47N/AN/AN/A-259.60%-45.86%-28.96%7/30/2025 (Estimated)OCGNOcugen-$54.05M-$0.19N/AN/AN/A-1,271.12%-223.00%-92.20%8/14/2025 (Estimated)REPLReplimune Group-$247.30M-$3.07N/AN/AN/AN/A-57.98%-45.21%8/14/2025 (Estimated)TBIOTelesis Bio-$47.72M-$28.20N/A∞N/A-336.59%N/A-61.89%8/5/2025 (Estimated)Latest ALEC, REPL, CCCC, OCGN, and TBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CCCCC4 Therapeutics-$0.41N/AN/AN/A$5.24 millionN/A8/6/2025Q2 2025ALECAlector-$0.45N/AN/AN/A$2.76 millionN/A5/22/2025Q4 2025REPLReplimune Group-$0.75-$0.82-$0.07-$0.82N/AN/A5/9/2025Q1 2025OCGNOcugen-$0.06-$0.05+$0.01-$0.05N/A$1.48 million5/7/2025Q1 2025CCCCC4 Therapeutics-$0.48-$0.37+$0.11-$0.37$3.54 million$7.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/ACCCCC4 TherapeuticsN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ATBIOTelesis BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.103.343.34CCCCC4 TherapeuticsN/A5.705.70OCGNOcugen1.742.602.60REPLReplimune Group0.177.957.95TBIOTelesis BioN/A1.231.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%CCCCC4 Therapeutics78.81%OCGNOcugen10.27%REPLReplimune Group92.53%TBIOTelesis Bio37.63%Insider OwnershipCompanyInsider OwnershipALECAlector9.10%CCCCC4 Therapeutics8.73%OCGNOcugen4.42%REPLReplimune Group8.80%TBIOTelesis Bio24.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector27099.99 million90.89 millionOptionableCCCCC4 Therapeutics15071.01 million64.81 millionOptionableOCGNOcugen80292.03 million279.12 millionOptionableREPLReplimune Group21077.09 million70.30 millionOptionableTBIOTelesis Bio2001.80 million1.36 millionOptionableALEC, REPL, CCCC, OCGN, and TBIO HeadlinesRecent News About These CompaniesTelesis Bio Inc (TBIO) Stock Forums - Investing.comJune 29, 2025 | investing.comTelesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene SynthesisMay 28, 2025 | finance.yahoo.comTelesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA SynthesisMarch 20, 2025 | finance.yahoo.comTelesis Bio: Q3 Earnings SnapshotNovember 8, 2024 | timesunion.comTTelesis Bio Announces Departure of Chief Legal OfficerOctober 25, 2024 | markets.businessinsider.comTelesis Bio Shares Double After News of Beckman Coulter Life Sciences CollaborationSeptember 27, 2024 | marketwatch.comWhat's Going On With Telesis Bio Shares Thursday?September 27, 2024 | msn.comTelesis Bio Inc (TBIO) Stock: More Strategic Than Meets the EyeSeptember 27, 2024 | bovnews.comBTelesis Bio Stock Is Soaring Wednesday: What's Going On?September 26, 2024 | msn.comTelesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA SynthesisSeptember 25, 2024 | globenewswire.comThe TBIO Conundrum: Why Telesis Bio Inc’s Stock Is Making Headlines AgainSeptember 21, 2024 | bovnews.comBTelesis Bio Inc (TBIO) Stock: Greater Than Its Current Valuation?September 19, 2024 | bovnews.comBTelesis Bio Plans to Delist its Securities from The Nasdaq Stock MarketSeptember 10, 2024 | globenewswire.comTelesis Bio Names CEO Eric Esser as Chair After Five Board Members ResignAugust 30, 2024 | marketwatch.comTelesis Bio IncAugust 15, 2024 | money.usnews.comTBIO Stock Earnings: Telesis Bio Misses EPS, Misses Revenue for Q2 2024August 7, 2024 | msn.comTelesis Bio Reports Second Quarter and First Half 2024 Financial ResultsAugust 7, 2024 | finance.yahoo.comTelesis Bio (NASDAQ:TBIO) Stock, Short Interest ReportJuly 31, 2024 | benzinga.comTBIO Stock Earnings: Telesis Bio Misses EPS, Misses Revenue for Q1 2024May 10, 2024 | investorplace.comTelesis Bio Reports First Quarter 2024 Financial ResultsMay 9, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefensePayment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?By Gabriel Osorio-Mazilli | June 23, 2025View Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?ALEC, REPL, CCCC, OCGN, and TBIO Company DescriptionsAlector NASDAQ:ALEC$1.61 -0.11 (-6.40%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.61 0.00 (0.00%) As of 07/11/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.C4 Therapeutics NASDAQ:CCCC$2.23 +0.24 (+12.06%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.28 +0.04 (+2.02%) As of 07/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Ocugen NASDAQ:OCGN$1.14 -0.01 (-0.87%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.14 0.00 (-0.44%) As of 07/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.Replimune Group NASDAQ:REPL$10.97 +0.20 (+1.86%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$11.12 +0.15 (+1.32%) As of 07/11/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Telesis Bio NASDAQ:TBIO$0.30 0.00 (0.00%) As of 07/11/2025Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.